Radiation therapy in locally advanced pancreatic cancer with 75 Gy simultaneous integrated boost: a dosimetric feasibility study

Han ZHUANG; Chifang LING; Jiazhou WANG; Xu HAN; Rui JIANG; Weigang HU

doi:10.19401/j.cnki.1007-3639.2023.01.006

您当前的位置：

首页 >

文章列表页 >

Radiation therapy in locally advanced pancreatic cancer with 75 Gy simultaneous integrated boost: a dosimetric feasibility study

Article | 更新时间：2025-12-31

- Radiation therapy in locally advanced pancreatic cancer with 75 Gy simultaneous integrated boost: a dosimetric feasibility study
- China Oncology Vol. 33, Issue 1, Pages: 54-60(2023)
- 作者机构：
  
  复旦大学附属肿瘤医院放射治疗中心，复旦大学上海医学院肿瘤学系，上海市放射肿瘤学重点实验室，上海市放射治疗临床医学研究中心，上海 200032
- 作者简介：
  
  HU Weigang.
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.01.006
  CLC： R735.9
- Received：31 August 2022，
  
  Revised：2022-10-25，
  
  Published：30 January 2023
- 稿件说明：
移动端阅览
Han ZHUANG, Chifang LING, Jiazhou WANG, et al. Radiation therapy in locally advanced pancreatic cancer with 75 Gy simultaneous integrated boost: a dosimetric feasibility study[J]. China Oncology, 2023, 33(1): 54-60.
DOI：

Han ZHUANG, Chifang LING, Jiazhou WANG, et al. Radiation therapy in locally advanced pancreatic cancer with 75 Gy simultaneous integrated boost: a dosimetric feasibility study[J]. China Oncology, 2023, 33(1): 54-60. DOI： 10.19401/j.cnki.1007-3639.2023.01.006.

摘要

背景与目的：

近年来，胰腺癌的发病率逐年上升，调强放射治疗（intensity-modulated radiotherapy，IMRT）已被广泛应用于胰腺癌的治疗，但多数胰腺癌IMRT的剂量学研究的处方剂量都小于60 Gy。本研究旨在探究局部晚期胰腺癌（locally advanced pancreatic cancer，LAPC）患者75 Gy同步加量放射治疗的剂量可行性并比较共面IMRT（coplanar IMRT，CO-IMRT）与非共面IMRT（non-coplanar IMRT，NC-IMRT）技术的剂量学差异。

方法：

纳入复旦大学附属肿瘤医院2018年1月—2021年12月收治的符合入组标准的10例接受同步加量放射治疗的LAPC患者，处方剂量为50 Gy的计划靶区（planning target volume，PTV），记为PTV

50 Gy

，处方剂量为75 Gy同步加量的PTV，记为PTV

75 Gy

，靶区照射分次均为25次。为每例患者分别设计CO-IMRT和NC-IMRT计划。同1例患者两种计划的射野数、处方剂量和危及器官（organs at risk，OAR）的优化条件完全相同。统计CO-IMRT和NC-IMRT计划的靶区剂量分布、适形性指数（conformity index，CI）、均匀性指数（homogeneity index，HI）、OAR剂量学结果、出束时间和机器跳数（monitor units，MU）。评估靶区是否满足临床要求以及OAR剂量限值是否符合临床正常组织效应定量分析（quantitative analysis of normal tissue effects in the clinic，QUANTEC）要求，并比较CO-IMRT计划与NC-IMRT计划之间的剂量学差异。

结果：

CO-IMRT和NC-IMRT均可达到靶区剂量覆盖要求并满足QUANTEC的剂量限值要求。两种PTV的CI、HI、出束时间和MU之间的差异无统计学意义（

0.05）。在左侧肾

mean

[（10.15±1.53）Gy

（9.29±1.78）Gy，

0.05

]

、左侧肾

[（32.74±7.45）%

（26.03±8.97）%，

0.05

]

、右侧肾

mean

[（7.37±2.41）Gy

（6.62±2.37）Gy，

0.05

]

、右侧肾

[（22.27±10.30）%

（14.94±8.62）%，

0.05

]

、肝

[（6.37±4.05）%

（5.47±3.70）%，

0.05

]

、小肠

[（9.96±6.66）%

（8.73±6.19）%，

0.05

]

、小肠

[（1.15±0.71）%

（0.96±0.61）%，

0.05

]

、胃

[（5.37±3.96）%

（4.52±3.32）%，

0.05

]

、大肠

[（13.18±4.95）%

（9.19±4.94）%，

0.05

]

指标上，NC-IMRT显著优于CO-IMRT，差异有统计学意义（

0.05）。在脊髓

max

、肝

mean

、双侧肾

、小肠

max

、胃

max

和十二指肠

55（mL）

指标上，CO-IMRT与NC-IMRT之间差异无统计学意义（

0.05）。

结论：

基于75 Gy同步加量放射治疗治疗LAPC时，CO-IMRT和NC-IMRT均能达到靶区剂量覆盖要求并满足OAR剂量限值。在不影响靶区剂量覆盖质量的前提下，NC-IMRT在双肾、肝和胃肠道的剂量分布上更有优势，能够更好地保护OAR，降低放射治疗对胃肠道、肝和肾的毒性。

Abstract

Background and purpose:

The incidence of pancreatic cancer has increased annually. Intensity-modulated radiotherapy (IMRT) has been widely used in the treatment of pancreatic cancer

however most dosimetric studies for pancreatic cancer have prescribed doses less than 60 Gy. The purpose of this study was to investigate the feasibility and dosimetric differences between coplanar IMRT (CO-IMRT) and non-coplanar IMRT (NC-IMRT) when using 75 Gy simultaneous integrated boost for patients with locally advanced pancreatic cancer (LAPC).

Methods:

Ten patients with LAPC treated with simultaneous integrated boost at Fudan University Shanghai Cancer Center from January 2018 to December 2021 were included. The prescribed dose for the planning target volume (PTV)

50 Gy

was 50 Gy in 25 fractions

and 75 Gy in 25 fractions for the simultaneous integrated boost PTV

75 Gy

. CO-IMRT and NC-IMRT plans were designed for each patient separately

with identical number of fields

prescription doses and OAR constrains for the same patient. The PTV dose distribution

conformability index (CI)

homogeneity index (HI)

indices to organs at risk (OAR) for multiple end points

beam-on time and monitor units (MU) were analyzed. We evaluated whether the PTV met clinical requirements and quantitative analysis of normal tissue effects in the clinic (QUANTEC) limits

and compared do

simetric differences between the two plans.

Results:

Both CO-IMRT and NC-IMRT could achieve the required dose coverage of PTV and meet the QUANTEC dose limits for OAR. The differences in CI

beam-on time and MU between the two plans were not statistically significant (

0.05). NC-IMRT was significantly decreased left kidney

mean

[(10.15±1.53) Gy

(9.29±1.78) Gy

0.05

]

left kidney

[(32.74±7.45)%

(26.03±8.97)%

0.05

]

right kidney

mean

[(7.37±2.41) Gy

(6.62±2.37)Gy

0.05

]

right kidney

[(22.27±10.30)%

(14.94±8.62)%

0.05

]

liver

[(6.37±4.05)%

(5.47±3.70)%

0.05

]

small intestine

[(9.96±6.66)%

(8.73±6.19)%

0.05

]

small intestine

[(1.15±0.71)%

(0.96±0.61)%

0.05

]

stomach

[(5.37±3.96)%

(4.52±3.32)%

0.05

]

and large bowel

[(13.18±4.95)%

(9.19±4.94)%

0.05

]

. There was no significant difference between CO-IMRT and NC-IMRT in spinal cord

max

liver

mean

bilateral renal

small intestinal

max

gastric

max

and duodenal

55(mL)

(

0.05).

Conclusion:

In the treatment of LAPC using 75 Gy simultaneous integrated boost

both CO-IMRT and NC-IMRT can achieve excellent PTV coverage and meet the OAR co

nstraints in all patients. Without affecting the quality of PTV coverage

NC-IMRT has more advantages in the dose distribution of OAR

which can better protect the OAR and reduce the toxicity to the gastrointestinal tract

liver and kidneys.

关键词

Keywords

references

SIEGEL R L , MILLER K D , JEMAL A . Cancer statistics, 2018 [J ] . CA A Cancer J Clin , 2018 , 68 ( 1 ): 7 - 30 . DOI: 10.3322/caac.21442 http://doi.org/10.3322/caac.21442 http://doi.wiley.com/10.3322/caac.21442 http://doi.wiley.com/10.3322/caac.21442

RAMESH H . Management of pancreatic cancer: current status and future directions [J ] . Indian J Surg , 2010 , 72 ( 4 ): 285 - 289 . DOI: 10.1007/s12262-010-0123-3 http://doi.org/10.1007/s12262-010-0123-3

REYNGOLD M , O’REILLY E M , VARGHESE A M , et al . Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer [J ] . JAMA Oncol , 2021 , 7 ( 5 ): 735 - 738 . DOI: 10.1001/jamaoncol.2021.0057 http://doi.org/10.1001/jamaoncol.2021.0057

REYNGOLD M , PARIKH P , CRANE C H . Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results [J ] . Radiat Oncol , 2019 , 14 ( 1 ): 95 . DOI: 10.1186/s13014-019-1309-x http://doi.org/10.1186/s13014-019-1309-x

MARKS L B , YORKE E D , JACKSON A , et al . Use of normal tissue complication probability models in the clinic [J ] . Int J Radiat Oncol Biol Phys , 2010 , 76 ( 3 Suppl ): S10 - S19 . DOI: 10.1016/j.ijrobp.2009.07.1754 http://doi.org/10.1016/j.ijrobp.2009.07.1754 https://linkinghub.elsevier.com/retrieve/pii/S036030160903288X https://linkinghub.elsevier.com/retrieve/pii/S036030160903288X

HODAPP N . The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT) [J ] . Al , 2012 , 188 ( 1 ): 97 - 99 .

IACOBUZIO-DONAHUE C A , FU B J , YACHIDA S , et al . DPC 4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer [J ] . J Clin Oncol , 2009 , 27 ( 11 ): 1806 - 1813 . DOI: 10.1200/JCO.2008.17.7188 http://doi.org/10.1200/JCO.2008.17.7188 https://ascopubs.org/doi/10.1200/JCO.2008.17.7188 https://ascopubs.org/doi/10.1200/JCO.2008.17.7188

CRANE C H , VARADHACHARY G R , YORDY J S , et al . Phase Ⅱ trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4 (Dpc4) immunostaining with pattern of disease progression [J ] . J Clin Oncol , 2011 , 29 ( 22 ): 3037 - 3043 . DOI: 10.1200/JCO.2010.33.8038 http://doi.org/10.1200/JCO.2010.33.8038 https://ascopubs.org/doi/10.1200/JCO.2010.33.8038 https://ascopubs.org/doi/10.1200/JCO.2010.33.8038

GUTT R , LIAUW S L , WEICHSELBAUM R R . The role of radiotherapy in locally advanced pancreatic carcinoma [J ] . Nat Rev Gastroenterol Hepatol , 2010 , 7 ( 8 ): 437 - 447 . DOI: 10.1038/nrgastro.2010.98 http://doi.org/10.1038/nrgastro.2010.98

RUDRA S , JIANG N M , ROSENBERG S A , et al . Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer [J ] . Cancer Med , 2019 , 8 ( 5 ): 2123 - 2132 . DOI: 10.1002/cam4.2100 http://doi.org/10.1002/cam4.2100 https://onlinelibrary.wiley.com/doi/10.1002/cam4.2100 https://onlinelibrary.wiley.com/doi/10.1002/cam4.2100

KRISHNAN S , CHADHA A S , SUH Y , et al . Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation [J ] . Int J Radiat Oncol Biol Phys , 2016 , 94 ( 4 ): 755 - 765 . DOI: 10.1016/j.ijrobp.2015.12.003 http://doi.org/10.1016/j.ijrobp.2015.12.003 https://linkinghub.elsevier.com/retrieve/pii/S0360301615268101 https://linkinghub.elsevier.com/retrieve/pii/S0360301615268101

SMYTH G , EVANS P M , BAMBER J C , et al . Recent developments in non-coplanar radiotherapy [J ] . Br J Radiol , 2019 , 92 ( 1097 ): 20180908 . DOI: 10.1259/bjr.20180908 http://doi.org/10.1259/bjr.20180908 https://www.birpublications.org/doi/10.1259/bjr.20180908 https://www.birpublications.org/doi/10.1259/bjr.20180908

STEFANOWICZ S , STÜTZER K , ZSCHAECK S , et al . Comparison of different treatment planning approaches for intensity-modulated proton therapy with simultaneous integrated boost for pancreatic cancer [J ] . Radiat Oncol , 2018 , 13 ( 1 ): 228 . DOI: 10.1186/s13014-018-1165-0 http://doi.org/10.1186/s13014-018-1165-0

DONG P , LEE P , RUAN D , et al . 4π non-coplanar liver SBRT: a novel delivery technique [J ] . Int J Radiat Oncol Biol Phys , 2013 , 85 ( 5 ): 1360 - 1366 . DOI: 10.1016/j.ijrobp.2012.09.028 http://doi.org/10.1016/j.ijrobp.2012.09.028 https://linkinghub.elsevier.com/retrieve/pii/S036030161203636X https://linkinghub.elsevier.com/retrieve/pii/S036030161203636X

SOYFER V , CORN B W , MELAMUD A , et al . Three-dimensional non-coplanar conformal radiotherapy yields better results than traditional beam arrangements for adjuvant treatment of gastric cancer [J ] . Int J Radiat Oncol Biol Phys , 2007 , 69 ( 2 ): 364 - 369 . DOI: 10.1016/j.ijrobp.2007.03.032 http://doi.org/10.1016/j.ijrobp.2007.03.032 https://linkinghub.elsevier.com/retrieve/pii/S0360301607005123 https://linkinghub.elsevier.com/retrieve/pii/S0360301607005123

CHU J C , SOLIN L J , HWANG C C , et al . Three-dimensional dosimetric comparison of radiation therapy treatment planning of the pancreas [J ] . Med Dosim , 1992 , 17 ( 4 ): 199 - 203 .

DIAZ L , UREFIA A , CASTRO I , et al . 2062 POSTER comparative study between coplanar and non-coplanar techniques in radiotherapy of abdominal tumours [J ] . Eur J Cancer , 2011 , 47 : S206 - S207 .

Views

2488

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical feasibility study of a 2D ripple filter to improve the efficiency of carbon ion therapy

Application of generalized equivalent uniform dose optimization in the treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy

Preliminary study on involving field irradiation radiotherapy in neoadjuvant chemoradiotherapy for esophageal cancer

Dosimetric study of simplified intensity-modulated radiation therapy for nasopharyngeal carcinoma

Related Author

Jingfang ZHAO

Rongcheng HAN

Yinxiangzi SHENG

Nicki SCHLEGEL

Lijia ZHANG

Xiaochen NI

Xiaoshen WANG

Shengwei LI

Related Institution

Department of Medical Physics, Shanghai Proton and Heavy Ion Center

Shanghai Key Laboratory of Radiation Oncology

Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy

Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Department of Radiotherapy, Eye & ENT Hospital of Fudan University

AI问答

⁰